Rachel G.
- Country
- Belgium
- Department
- Medical oncology
Research Overview
- Dose-Escalation Study of Obrixtamig (BI 764532) and Ezabenlimab in DLL3-Expressing Neuroendocrine Neoplasms and Small Cell Lung Carcinoma
- Evaluation of the Safety, Tolerability, and Efficacy of the Pan-KRAS Inhibitor LY4066434 in Patients with KRAS Mutant Advanced Solid Tumors
- Evaluation of BI 764532 in Combination with Standard of Care for Tolerability in Patients with Extensive-Stage Small Cell Lung Carcinoma
Data & Insights
Has run more than one trial at 77 of 160 partner sites.
Specializations
Lung Cancer Research
This investigator specializes in treating various forms of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with particular emphasis on advanced and metastatic cases.
- Metastatic non-squamous NSCLC treatment
- EGFR-mutated lung cancer therapy
- DLL3-expressing small cell carcinomas
- KRAS G12C mutation treatments
The investigator explores novel therapeutic combinations including immunotherapy and targeted treatments for lung cancer patients.
Advanced Solid Tumors
Focuses on developing treatments for advanced and metastatic solid tumors, particularly investigating novel therapeutic approaches and drug combinations.
- Neuroendocrine carcinomas
- KRAS mutant solid tumors
- Inoperable locally advanced tumors
- Renal cell carcinoma
Expertise extends to evaluating innovative treatment strategies for patients with limited therapeutic options.
Therapeutic Innovation
Specializes in evaluating novel therapeutic compounds and their combinations with established treatments.
- Immunotherapy combinations
- Targeted therapy approaches
- Multi-drug treatment strategies
- Platinum-based therapy combinations
The investigator studies advanced therapeutic approaches for patients with complex oncological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.